Drug Profile
Insulin degludec/liraglutide - Novo Nordisk
Alternative Names: IDegLira; Insulin degludec/Victoza; Liraglutide/insulin degludec; Liraglutide/NN 1250; Liraglutide/Tresiba; NN 1250/liraglutide; NN-9068; Tresiba/liraglutide; Victoza/insulin degludec; XultophyLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Class Antihyperglycaemics; Glucagon-like peptides; Insulins; Pancreatic hormones
- Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon receptor antagonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 2 diabetes mellitus
Most Recent Events
- 31 Jul 2023 Novo Nordisk and Population Health Research Institute completes a phase III REMITiDegLira trial for Type-2 diabetes mellitus in Canada (SC) (NCT03862716)
- 29 Mar 2023 No development reported - Phase-III for Type 2 diabetes mellitus (Adjunctive treatment, Treatment-experienced) in Hong Kong, China (SC)
- 08 Jul 2022 Novo Nordisk completes a phase III IDegLira HIGH trial in Type 2 diabetes mellitus in USA (SC) (NCT03737240)